advanced head and neck cancer
Conditions
Interventions
Case series:Induction of chemotherapy for two cycles: tiggio + recombinant human endostatin
followed by intensity modulated radiotherapy combined with two cycles of recombinant human endostatin.
Sponsors
The Cancer Hospital of GuiZhou Province
Eligibility
Sex/Gender
All
Age
70 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary participation and written consent of written consent; 2. Age> 70 years old, sex is not limited; 3. Organically proved to be nasopharyngeal carcinoma or head and neck squamous cell carcinoma; 4. 2010UICC staging III-IVA, IVB period; 5. Primary tumors can be measured; 6. Card score =70; ECOG = 2; 7. The daily living ability of the Barthel index was assessed as mildly dependent (60-99 points); 8. Survival expected = 6 months; 9. Hemoglobin (HGB) =100 g/L, white blood cell (WBC) = 4×10^9/L, platelet (PLT) =100×10^9/L (Or white blood cells and platelets not less than the lowest laboratory value); 10. liver function: alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) <normal upper limit (ULN) 1.5 times; total bilirubin <1.5×ULN; 11. renal function: serum creatinine <1.5×ULN; 12. Left ventricular ejection fraction (LVEF) in the normal range (55% - 65%); 13. All uncontrollable complications such as hypertension, diabetes, coronary heart disease and mental history; 14. The treatment for the first course of treatment (no head and neck radiotherapy history; no concurrent; radiotherapy and chemotherapy history; 3 months without chemotherapy.
Exclusion criteria
Exclusion criteria: There is a distant shift. 2. Primary tumor or lymph node surgery has been surgery (except biopsy). 3. Primary lesions or lymph nodes were radiotherapy. 4. Has received epidermal growth factor targeted therapy. 5. Primary lesions have received chemotherapy or immunotherapy. 6. had other malignancies (except for cured basal cell carcinoma or cervical cancer). 7. Subjects who have received other drug tests in the past month. 8. > Class ? peripheral neuropathy. 9. Have a serious history of allergies or specific physical. 10. A history of severe lung or heart disease. 11. Reject or not be able to sign informed consent for trial. 12. Abuse of drugs or alcohol addicts. 13. Person who has personality or mental illness, no civil capacity or limited civil capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EORTC Quality of Life Measurement Scale;Observation of acute toxicity of neoadjuvant chemotherapy (1);Synchronous radiotherapy and chemotherapy acute toxicity table (a); | — |
Countries
China
Contacts
Public ContactLi yuanyuan
The Cancer Hospital of GuiZhou Province
Outcome results
None listed